63.49

0.41% -0.26

Royalty Pharma Plc (RPRX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

$63.75

Aprire:

$63.5

Volume 24 ore:

1.24M

Relative Volume:

0.39

Capitalizzazione di mercato:

$28.27B

Reddito:

$2.44B

Utile/perdita netta:

$1.36B

Rapporto P/E:

33.25

EPS:

1.9093

Flusso di cassa netto:

$574.14M

1 W Prestazione:

+4.15%

1M Prestazione:

+10.13%

6M Prestazione:

+27.90%

1 anno Prestazione:

+72.29%

Intervallo 1D:

$63.01

$63.84

Intervallo di 1 settimana:

$60.04

$63.84

Portata 52W:

$35.91

$64.38

Royalty Pharma Plc Stock (RPRX) Company Profile

Nome

Royalty Pharma Plc

Settore

Healthcare (1051)

Industria

Biotechnology (594)

Telefono

(212) 883-0200

Indirizzo

110 EAST 59TH STREET, NEW YORK, NY

Dipendente

100

Cinguettio

Prossima data di guadagno

2026-11-04

Ultimi documenti SEC

RPRX's Discussions on Twitter

Compare RPRX vs VRTX, REGN, MRNA, ARGX, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
RPRX Royalty Pharma Plc	63.49	28.27B	2.44B	1.36B	574.14M	1.9093
VRTX Vertex Pharmaceuticals Inc	524.82	133.02B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.02	82.98B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	201.18	80.32B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	874.54	55.00B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	377.04	42.65B	5.76B	514.49M	1.10B	4.4813

Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-30	Aggiornamento	UBS	Neutral → Buy
2025-09-30	Iniziato	Goldman	Buy
2025-05-16	Iniziato	Morgan Stanley	Overweight
2024-06-03	Downgrade	UBS	Buy → Neutral
2022-06-14	Ripresa	UBS	Buy
2022-05-13	Iniziato	Scotiabank	Sector Outperform
2022-04-27	Iniziato	Goldman	Buy
2022-04-14	Aggiornamento	JP Morgan	Neutral → Overweight
2022-04-06	Ripresa	Morgan Stanley	Overweight
2021-10-29	Aggiornamento	Citigroup	Neutral → Buy
2021-07-30	Iniziato	Tigress Financial	Buy
2020-11-09	Aggiornamento	UBS	Neutral → Buy
2020-07-14	Iniziato	Evercore ISI	In-line
2020-07-13	Iniziato	BofA Securities	Buy
2020-07-13	Iniziato	Citigroup	Neutral
2020-07-13	Iniziato	Cowen	Outperform
2020-07-13	Iniziato	Goldman	Neutral
2020-07-13	Iniziato	JP Morgan	Neutral
2020-07-13	Iniziato	Morgan Stanley	Equal-Weight
2020-07-13	Iniziato	SunTrust	Buy
2020-07-13	Iniziato	UBS	Neutral

Mostra tutto

Royalty Pharma Plc Borsa (RPRX) Ultime notizie

Oct 16, 2026

Royalty Pharma Announces Fourth-Quarter 2026 Dividend of $0.235 Per Class A Ordinary Share - Quiver Quantitative

Oct 16, 2026

Shareholders are set to get 23.5 cents per share from Royalty Pharma on Dec. 10. - Stock Titan

Oct 16, 2026

Oct 15, 2026

Global femtech market to reach $255.5B by 2035, driven by AI, telehealth, and personalized women's healthcare. - Pluang

Oct 15, 2026

Oct 13, 2026

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? - Zacks Investment Research

Oct 13, 2026

Oct 12, 2026

Form 4 Royalty Pharma Plc For: 12 October By Investing.com - Investing.com India

Oct 12, 2026

Royalty Pharma EVP Marshall Urist sells $235,594 in shares - Investing.com

Oct 12, 2026

Form 4 Royalty Pharma Plc For: 12 October By Investing.com - Investing.com Nigeria

Oct 12, 2026

Form 4 Royalty Pharma Plc For: 12 October By Investing.com - Investing.com UK

Oct 12, 2026

Oct 08, 2026

Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again - Zacks Investment Research

Oct 08, 2026

Oct 05, 2026

At $57.10 a share, Royalty Pharma (RPRX) EVP Marshall Urist sells 4,126 shares. - Stock Titan

Oct 05, 2026

Officer Marshall Urist proposes selling 4,126 Royalty Pharma (RPRX) shares. - Stock Titan

Oct 05, 2026

Oct 01, 2026

Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool

Oct 01, 2026

Sep 30, 2026

Form 4 Royalty Pharma Plc For: 30 September By Investing.com - Investing.com Nigeria

Sep 30, 2026

Form 4 Royalty Pharma Plc For: 30 September By Investing.com - Investing.com South Africa

Sep 30, 2026

Royalty Pharma EVP Marshall Urist sells $238,812 in shares - Investing.com

Sep 30, 2026

Form 4 Royalty Pharma Plc For: 30 September By Investing.com - Investing.com Canada

Sep 30, 2026

Royalty Pharma EVP Marshall Urist sells $238,812 in shares By Investing.com - Investing.com India

Sep 30, 2026

Form 4 Royalty Pharma Plc For: 30 September By Investing.com - Investing.com UK

Sep 30, 2026

A director acquires 642 shares in lieu of a $37,500 retainer at Royalty Pharma (RPRX). - Stock Titan

Sep 30, 2026

4,126 shares sold under a trading plan by Royalty Pharma (RPRX) EVP Marshall Urist. - Stock Titan

Sep 30, 2026

Sep 29, 2026

Form 144 Royalty Pharma plc For: 29 September By Investing.com - Investing.com Nigeria

Sep 29, 2026

Form 144 Royalty Pharma plc For: 29 September By Investing.com - Investing.com Canada

Sep 29, 2026

Form 144 Royalty Pharma plc For: 29 September By Investing.com - Investing.com South Africa

Sep 29, 2026

Form 144 Royalty Pharma plc For: 29 September By Investing.com - Investing.com UK

Sep 29, 2026

Sep 28, 2026

Royalty Pharma officer proposes $239K share sale | RPRX SEC FilingForm 144 - Stock Titan

Sep 28, 2026

Sep 27, 2026

Form 144 Royalty Pharma PLC For: 27 September By Investing.com - Investing.com Nigeria

Sep 27, 2026

Sep 25, 2026

Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com India

Sep 25, 2026

Royalty Pharma EVP Christopher Hite sells $5.85m in shares By Investing.com - Investing.com Canada

Sep 25, 2026

Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com Nigeria

Sep 25, 2026

Royalty Pharma EVP Christopher Hite sells $5.85m in shares - Investing.com

Sep 25, 2026

Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com Canada

Sep 25, 2026

Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com UK

Sep 25, 2026

Royalty Pharma EVP Christopher Hite sells $5.85m in shares By Investing.com - Investing.com UK

Sep 25, 2026

Sep 23, 2026